Onkologie. 2024:18(3):167-170 | DOI: 10.36290/xon.2024.030

Approach to treatment of visceral metastases in metastatic prostate cancer

Jana Katolická
Onkochirurgické oddělení, FN u svaté Anny, Brno

Combined treatment of metastatic hormone-sensitive prostate cancer and sequential treatment of metastatic castration-resistant prostate cancer significantly prolonged the survival of men with this disease. Patients with visceral metastases invariably have a worse prognosis than patients with bone-only metastase. Patients with liver metastases typically have the worst survival outcomes compared to those with bone metastases or other sites of visceral metastases.

Keywords: metastatic hormone-sensitive prostate cancer, metastatic castration-resistant prostate cancer, visceral metastasis, second novel hormonal therapy, chemotherapy.

Accepted: June 18, 2024; Published: June 24, 2024  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Katolická J. Approach to treatment of visceral metastases in metastatic prostate cancer. Onkologie. 2024;18(3):167-170. doi: 10.36290/xon.2024.030.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Shou J, Zhang Q, Wang S, Zhang D. The prognosis of different distant metastases pattern in prostate cancer: A population based retrospective study. Prostate. 2018;78(7):491-497. Go to original source... Go to PubMed...
    2. Whitney CA, Howard LE, Posadas EM, et al. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database. Eur Urol Focus. 2017;3(4-5):480-486. Go to original source... Go to PubMed...
    3. Akfirat C, Zhang X, Ventura A, et al. Tumour cell survival mechanisms in lethal metastatic prostate cancer differ between bone and soft tissue metastases. J Pathol. 2013;230(3):291-297. Go to original source... Go to PubMed...
    4. Cornford P, van den Bergh RCN, Briers E. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate cancer. EurUrol. 2021;79(2):263-282. Go to original source... Go to PubMed...
    5. Sung WWY, Choi HCW, Luk PHY, So TH. A cost-effectiveness analysis of systemic therapy for metastatic hormone-sensitive prostate cancer. Front Oncol. 2021;11:627083. Go to original source... Go to PubMed...
    6. Yanagisawa T, Rajwa P, Kawad T, et al. Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis. J Urol 2023;210(3):416-429. doi: 10.1097/JU. 0000000000003594. Go to original source... Go to PubMed...
    7. Kyriakopoulos CE, Chen YH, Carducci MA. Chemo-hormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805CHAARTED trial. J Clin Oncol. 2018;36(11):1080-1087. Go to original source... Go to PubMed...
    8. Chi K, Hotte SJ, Joshua AM. Treatment of mCRPC in the AR-axis-targeted therapy-resistantstate. Ann Oncol. 2015; 26(10):2044-2056. Go to original source... Go to PubMed...
    9. Pouessel D, Gallet B, Bibeau F. Liver metastasesin prostate carcinoma: clinical characteristics andoutcome. BJU Int. 2007;99(4):807-811. Go to original source... Go to PubMed...
    10. Koroki Y, Taguri M. Clinical outcomes offirst subsequent therapies after abiraterone acetateplus prednisone for high-risk metastatic castration-sensitive prostate cancer in the LATITUDE study. Target Oncol. 2022;18(1):119-128. Go to original source... Go to PubMed...
    11. Beer TM, Armstrong AJ, Rathkopf DE. Enzalutamide in metastatic prostate cancer before chemotherapy.N Engl J Med. 2014;371(5):424-433. Go to original source... Go to PubMed...
    12. de Wit R, de Bono J, Sternberg CN. Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer. N Engl J Med. 2019;381(26):2506-2518. Go to original source... Go to PubMed...
    13. Hussain M, Mateo J, Fizazi K. Survival with olaparib in metastatic castration-resistant pros-tate cancer. N Engl J Med. 2020;383(24):2345-2357. Go to original source... Go to PubMed...
    14. Sartor O, de Bono J, Chi KN. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med. 2021;385(12):1091-1103. Go to original source... Go to PubMed...
    15. Iwamoto H, Izumi K, Shimada T. Androgen receptor signaling-targeted therapy and taxane chemotherapy induce visceral metastasis in castration-resistant prostate cancer. Prostate. 2021;81(1):72-80. Go to original source... Go to PubMed...
    16. Agarwal N. Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT the Genitourinary (GU). American Society of Clinical Oncology (ASCO). Annual Meeting, San Francisco, CA, 25.-27. Jan. 2024.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.